Neurology in Ohio

Avation Medical develops and commercializes Vivally®, an FDA-cleared wearable at-home treatment system for overactive bladder (OAB) symptoms, including urgency urinary incontinence and frequency. The Vivally System combines a wearable ankle wrap, a wireless CliQ™ control module, and a mobile application to deliver physiologic closed-loop controlled transcutaneous tibial nerve stimulation (PCL TTNS) with continuous EMG sensing. The treatment regimen consists of 30-minute sessions administered three times weekly, allowing patients to manage therapy on their own schedule at home. Clinical evidence from multicenter prospective trials demonstrates that 84% of enrolled patients were responders experiencing significant improvement in OAB symptoms and quality of life, with sustained reductions in void, incontinence, and urgency episodes observed through 12 months of use. The system features high patient satisfaction rates and no significant device-related adverse events. Vivally targets a large addressable market: approximately 42 million Americans suffer from OAB and urge urinary incontinence. The platform supports remote monitoring and digital health capabilities, enabling providers to prescribe and calibrate therapy during a single office visit, then track patient progress remotely. Avation Medical provides comprehensive patient support including coverage coordination with major commercial payors, customer care services, and claims and billing assistance. The company markets the system to both patients seeking non-pharmacological OAB management and healthcare providers seeking to offer advanced therapeutic options.

Dormotech Medical Inc. is a medical device manufacturer specializing in wireless sleep diagnostic systems. The company develops and markets DormoVision X™, a comprehensive polysomnography (PSG) platform designed for both home sleep apnea testing (HSAT) and in-laboratory sleep studies. The system captures 29 direct physiological channels and 9 derived channels, including EEG, EOG, chin EMG, ECG, SpO₂, nasal/oral airflow, respiratory effort, snoring/breathing sounds, body and head position, and modular ExG measurements for leg, limb, and chest activity. DormoVision X™ is cloud-based and wireless, eliminating traditional wired equipment complexity while delivering in-lab quality diagnostic data. The platform supports all three sleep study types (Type 1, 2, and 3) and accommodates pediatric patients age 6 and older with patient-friendly wireless sensors and soft materials. Clinical validation demonstrates 97% equivalence with traditional in-lab PSG. The system enables unlimited multi-night testing to capture night-to-night variability and includes automated AI-driven analysis for sleep staging, arousal detection, and event classification. Dormotech targets sleep medicine clinics, hospitals, and diagnostic centers seeking to expand capacity without adding physical lab beds or overhead. The usage-based, scalable cloud model supports expansion across multiple locations. The company is recognized for innovation in sleep medicine and maintains an advisory board of leading sleep medicine physicians and researchers.

Mammotome is a global breast care company specializing in diagnostic and surgical solutions for breast cancer detection and treatment. The company manufactures vacuum-assisted breast biopsy systems, stereotactic biopsy devices, MR-guided biopsy platforms, and surgical marker navigation systems. Product portfolio includes the Mammotome PrimaTM MR System (in-room, vacuum-assisted MR breast biopsy), Mammotome RevolveTM and RevolveTM ST stereotactic biopsy systems, Mammotome DualCoreTM and Elite systems, Pintuition® surgical marker navigation system, Neoprobe® GDS gamma detection system, and comprehensive biopsy site markers (HydroMARKTM Plus, standard markers). The company serves 60 countries with 550+ associates across 9 global locations. Mammotome holds FDA clearances for its MR biopsy systems and markers, and Health Canada approval for the Pintuition® System. As a Danaher-owned company, Mammotome integrates advanced imaging compatibility and procedural efficiency into products designed for radiologists, surgeons, and pathologists in hospital and outpatient diagnostic centers.

Electro-Cap International, Inc. is a specialized medical device manufacturer headquartered in Eaton, Ohio, founded in 1988. The company is the world leader in electrode caps for electroencephalography (EEG) and related neurological applications. Their electrode caps serve as diagnostic tools for EEG testing, neurological assessment, neurofeedback protocols, and clinical research. The product line is used across hospitals, neurosurgery departments, psychology clinics, academic universities, and private research laboratories. Electro-Cap caps are designed to enable high-quality signal acquisition for functional brain diagnostics and monitoring. The company maintains a focus on quality and integrity in manufacturing. While specific regulatory certifications and detailed product specifications are not listed on the primary web presence, the company's long operational history and established market position indicate compliance with relevant medical device standards for EEG electrode systems.

SPR Therapeutics is a Cleveland-based medical device company specializing in peripheral nerve stimulation (PNS) technology for non-opioid, non-surgical pain management. Founded in 2010, the company develops innovative neuromodulation solutions targeting chronic pain, acute pain, post-surgical pain, and post-traumatic pain. The company's flagship product, the SPR® SPRINT® Peripheral Nerve Stimulation System, is the only FDA-approved percutaneous PNS system designed for both chronic and acute indications. SPR Therapeutics' mission centers on providing drug-free alternatives to opioids and invasive surgical procedures, directly addressing the opioid crisis. The company has demonstrated strong clinical evidence with over 200 patents, Department of Defense and NIH funding support, and real-world efficacy showing pain relief in over 70% of patients with more than 50,000 implants performed. SPR continues to advance next-generation pain therapies while expanding market coverage and clinical adoption.

Strolll Limited develops Reality DTx®, a digital therapeutic software platform for augmented reality (AR) glasses designed for neurorehabilitation. The solution uses transparent, see-through AR lenses that blend digital content with physical space, enabling clinicians to deliver immersive therapy in real-world environments—clinic or home. The platform captures objective, clinically relevant data during both in-clinic and at-home rehabilitation sessions, supporting remote monitoring and automated clinical documentation. Strolll integrates into existing clinical workflows for synchronous or asynchronous therapy delivery, reducing administrative burden while enabling real-time patient oversight. The platform addresses gait training, mobility improvement, fall prevention, and functional recovery across neurological conditions including Parkinson's disease, stroke, and generalized balance disorders. Regulatory credentials include CE marking, UKCA certification, FDA clearance, NHS Data Security and Protection Toolkit (DTAC) compliance, and DCB0129 designation. The company collaborates with NHS facilities, private rehabilitation centers, physiotherapy practices, and academic institutions across the UK and US. Target users are physical therapists, occupational therapists, and rehabilitation specialists managing both outpatient and home-based programs.

Great Lakes NeuroTechnologies (GLNT) is a biomedical technology company specializing in physiological monitoring systems and patient-centered diagnostic platforms for movement disorders, telemedicine, and in-home health monitoring. Founded in 2010 and based in Independence, Ohio, GLNT designs, manufactures, and distributes wireless and web-based bioinstrumentation products for clinical, research, and educational applications. The company's primary offerings include the Kinesia line of wearable systems for real-time motor symptom assessment in Parkinson's disease and essential tremor, and the BioRadio wireless data acquisition platform for research and education. GLNT holds over 50 patents in neurological and movement disorder monitoring, with recent innovations in AI-driven therapy adjustment and remote deep brain stimulation (DBS) programming. The company serves physicians, medical technicians, healthcare practitioners, researchers, universities, and hospitals, addressing clinical needs in remote patient monitoring, clinical trial management, and therapy optimization.

Synapse Biomedical Inc. is an FDA-approved medical device company specializing in neurostimulation products for treating chronic respiratory insufficiency. Founded in 2002 and based in Oberlin, Ohio, the company develops minimally invasive diaphragm pacing systems designed to reduce mechanical ventilator dependence in patients with spinal cord injuries, amyotrophic lateral sclerosis (ALS), and other neurological conditions. The company's flagship product, the NeuRx® Diaphragm Pacing System (DPS), electrically stimulates the diaphragm to assist ventilation and restore respiratory muscle function. With over 2,000 patients successfully treated and coverage by Medicare, Medicaid, and private insurance, Synapse continues to advance respiratory care standards. The company also offers the TransAeris® system for preventing ventilator-induced diaphragm dysfunction (VIDD) in critically ill patients requiring temporary stimulation.

NeuroWave Systems Inc. is a medical device manufacturer specializing in advanced brain monitoring technologies for anesthesia, sedation, and critical care applications. Founded in 2007 as a spin-off from CleveMed, the company develops innovative EEG-based monitoring systems that provide real-time assessment of brain function and anesthetic effect. The flagship NeuroSENSE® Monitor delivers bilateral brain indices, enabling clinicians to detect asymmetries in brain function and optimize patient-specific drug delivery. The company's product portfolio includes the NeuroSENSE OEM Module for third-party integration and specialized electrodes for high-quality signal acquisition. NeuroWave targets operating rooms, ICUs, and anesthesia departments, emphasizing automation in anesthesia protocols to improve patient safety and reduce healthcare costs through precise, data-driven sedation management.

Surgical Theater, Inc. develops eXperiential Reality (XR) platforms that transform 2D medical imaging (MRI, CT, DTI) into interactive 3D surgical models using AI-driven reconstruction technology. The company serves neurosurgery, spine surgery, and otolaryngology specialties with three primary solutions: PlanXR™ for preoperative surgical planning and rehearsal; Brain STORM™ for epilepsy care management; and SyncAR® (Spine and Cranial variants) for real-time intraoperative augmented reality visualization. Additional products include XR Studio™ for multidisciplinary case reviews and education within XR headsets, and ConveyXR™ for patient engagement and informed consent. The platform enables surgeons to visualize patient-specific anatomy, identify critical structures (nerves, blood vessels), and simulate complex procedures before entering the operating room. Deployed at leading academic medical centers including Mayo Clinic, Stanford, Mount Sinai, Houston Methodist, UCSF, and NYU Langone, among others. The technology derives from advanced flight simulation methodologies applied to surgical visualization. Regulatory status and specific FDA clearances not explicitly stated on fetched content, though clinical research studies referenced. Serves both academic and community hospital markets internationally.